Expression of CD133 in various premalignant and proliferative lesions

Amtha, Rahmi; Gunardi, Indrayadi; Sandra, Ferry; Ernawati, Diah Savitri

doi:10.20473/j.djmkg.v48.i2.p64-68

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD133 is a transmembrane glycoprotein, which contains 865 amino acids with a molecular weight of 120 kDalton (10). CD133 function is unknown, but it increases in alteration processes including biological stress.…”

Section: Discussionmentioning

confidence: 99%

Literature review of cancer stem cells in oral lichen planus: a premalignant lesion

Moosavi¹,

Tavakol²

2021

Stem Cell Investig

View full text Add to dashboard Cite

Objective: As there is no review study about cancer stem cells (CSCs) involved in the pathogenesis of oral lichen planus (OLP), for the first time we review the role of these cells in OLP and this hypothesis may be a clue for the evaluation of the premalignancy of OLP.Background: Cellular mediated immune responses are the main etiopathogenesis in OLP and it is a potentially premalignant lesion. One of the factors proposed in the pathogenesis of OLP and the comparable trend of this autoimmune disease to squamous cell carcinoma (SCC) are CSCs. CSCs have been detected in several solid tumors including head and neck cancers, and have special characteristics including metastasis and resistance to chemotherapy.Methods: Related keywords were searched and risk of bias assessment was done for each study.Conclusions: Among all of the studies reviewed in this article, all markers had increased expression in OLP compared to controls that are consistent with SCC. Only CD44 was in contradiction to other papers, in which different expression of CD44 strains was measured in different samples such as saliva and tissue.Based on the results of this review and more studies in the future by investigating the levels of these markers in OLP, it may be possible to determine the prognosis and course of the disease for each patient individually.

show abstract

Section: Discussionmentioning

confidence: 99%

Literature review of cancer stem cells in oral lichen planus: a premalignant lesion

Moosavi¹,

Tavakol²

2021

Stem Cell Investig

View full text Add to dashboard Cite

show abstract

“…Expression of CD133 was also correlated with expression of drug resistance genes in nonsmall cell lung cancer (NSCLC) (Salnikov, et al, 2010). In addition, CD133 was reported to be correlated with premalignancy in oral tissue (Amtha, et al, 2015). Meanwhile CD44 expression was reported to be correlated with the risk of metastasis in gastric (Okayama, et al, 2009) and breast cancers (Celebiler Cavusoglu, et al, 2009).…”

Section: Csc In Pgxmentioning

confidence: 99%

A Brief Outlook on Pharmacogenetics (PGx): Focus in MicroRNAs (miRNAs) and Cancer Stem Cells (CSCs)

Sandra

2019

Indones J Cancer Chemoprevent

Self Cite

View full text Add to dashboard Cite

It has been known that there are differences in response to medications both in terms of clinical activity and side effects. Among all influencing factors, genetic variation has been considered to play a crucial part. By genetic investigation, the differences in drug metabolism, transport and target could be disclosed. Termed as “pharmacogenetics (PGx)”, that focuses on the variants within one or more candidate genes. Genetic tests have been started for screening polymorphisms prior to drug prescription, moreover many biomarkers were developed in oncology. Recent PGx investigations have been conducted to identify mRNAs, microRNAs (miRNAs) and other downstream signals that are affected by variation in genes that might cause drug response variability. Another intriguing study related to PGx in cancer stem cells (CSCs) has recently aroused. CSC shows more resistant behavior to drug. CSCs are subpopulation of cells, which share some same markers with stem cells. CSC can induce specific signal transduction pathways. Variation in genes affect CSCs activity are generally neglected in the past PGx studies. This could be one of the explanation why past PGx studies in cancer cell do not achieve optimal clinical outcome. Keywords : pharmacogenetics, pharmacogenomics, microRNAs, cancer stem cells

show abstract

Expression of CD133 in various premalignant and proliferative lesions

Cited by 2 publications

References 25 publications

Literature review of cancer stem cells in oral lichen planus: a premalignant lesion

Literature review of cancer stem cells in oral lichen planus: a premalignant lesion

A Brief Outlook on Pharmacogenetics (PGx): Focus in MicroRNAs (miRNAs) and Cancer Stem Cells (CSCs)

Contact Info

Product

Resources

About